Regeneron Pharmaceuticals ((REGN)), Sanofi SA ((SNY)), Sanofi ((DE:SNW)), Sanofi ((SNYNF)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Study Overview: The study titled An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Dupilumab in Patients ≥6 Months to <18 Years of Age With Atopic Dermatitis aims to evaluate the long-term safety and efficacy of Dupilumab in pediatric patients with atopic dermatitis. This research is significant as it seeks to provide insights into the prolonged use of Dupilumab, potentially improving treatment strategies for young patients with this chronic skin condition.
Intervention/Treatment: The intervention being tested is Dupilumab, a drug administered subcutaneously with weight-tiered dosing. It is intended to treat atopic dermatitis by reducing inflammation and improving skin condition.
Study Design: This is a Phase 3 interventional study with a non-randomized, parallel assignment model. There is no masking involved, and the primary purpose is treatment. The study involves different dosing schedules based on the participant’s body weight.
Study Timeline: The study began on October 15, 2015, with the latest update submitted on June 24, 2025. These dates are crucial as they indicate the study’s duration and the ongoing commitment to assessing the drug’s long-term effects.
Market Implications: The ongoing study of Dupilumab could positively impact Regeneron Pharmaceuticals and Sanofi’s stock performance by reinforcing investor confidence in their product pipeline. As the study progresses, it may also influence the competitive landscape in the treatment of atopic dermatitis, potentially affecting market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.